CYTX News and Press, Cytori Therapeutics Inc. From 03/07/19

SAN DIEGO, March 07, 2019 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc.  (NASDAQ: CYTX) today announced that it officially filed a formal new drug application pre-submission request to the European Medicine Agency (EMA) for Doxorubicin Hydrochloride Cytori. This submission is the pr...

Cytori Therapeutics (NASDAQ: CYTX ) has filed a prospectus for an unspecified public offering of Class A and Class B Units. More news on: Cytori Therapeutics Inc, Healthcare stocks news, Stocks on the move, Read more ...

Thinly traded nano cap Cytori Therapeutics ( CYTX +12.1% ) is up on an 11x surge in volume in reaction to the publication in the journal Gastroenterology of results from an investigator-initiated pilot study in France assessing Cytori Cell Therapy for the treatment of perianal fistula ...

SAN DIEGO, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc.  (NASDAQ: CYTX) announces the publication of results from a pilot investigator-initiated clinical trial of Cytori Cell Therapy™ for the treatment of refractory perianal fistula in patients with Crohnȁ...